Abstract
We may never have a cure for cancer, but a new type of drug, called radioconjugates, is grabbing the attention of oncologists. Like external radiation therapy, these drugs use radiation to kill tumors, but they do it internally with the help of cancer-seeking guides. Biotech firms are springing up to study and develop radioconjugates, joining big companies like AstraZeneca, Bayer, and Novartis. The US Food and Drug Administration has already approved two radioconjugate drugs: Lutathera and Pluvicto. Scientists have more work to do to design these drugs and make them targetable while finding and sourcing the right radioisotopes. Still, many see this new class of molecules as a promising part of future cancer treatments. Peter Boerner ran out of cancer treatments in the spring of 2015. Up to that point, he had tried pretty much every option, including surgery when he was first diagnosed with stage 3 prostate cancer in
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
